https://www.selleckchem.com/products/abbv-cls-484.html Radiolabeled somatostatin analogs for somatostatin receptor (SSTR)-targeted imaging and peptide receptor radionuclide therapy (PRRT) have demonstrated remarkable success in the management of SSTR-expressing neuroendocrine neoplasms. Primary neuroendocrine breast carcinoma is rare. Heterogeneous SSTR overexpression has also been documented in breast cancer, in both human breast cancer specimens and clinical studies. We report here a case of a 69-year-old woman who had both breast invasive ductal carcinoma and primary large-cell neuroendocrine breast carcinoma (Ki-67 proliferation index of 20%), with disseminated bone and lymph node metastases, demonstrating exceptional tracer uptake on Ga-DOTATOC PET/CT, and remarkably partial remission after Lu-DOTATOC PRRT.An 87-year-old woman with leg-type lymphoma underwent a staging F-FDG PET/CT, which demonstrated besides leg lymphomatous lesions a round, well-defined, preduodenal mass with moderate FDG uptake. This mass remained unchanged after chemotherapy treatment completion, despite a complete metabolic response of lymphomatous lesions. A biopsy revealed a gangliocytic paraganglioma. Subsequent F-FDOPA PET/CT and somatostatin receptor scintigraphy were positive and did not depict any other lesions.PHAT (pleomorphic hyalinizing angiectatic tumor) is a rare, locally aggressive, low-grade mesenchymal neoplasm of uncertain lineage with a predilection for the lower extremities. We report a 74-year-old woman with an enlarging mass on the right popliteal fossa undergoing FDG PET/CT to characterize its biological activity. Increased accumulation of FDG (SUVmax, 23.0) in the solid component of the tumor was seen. Diagnosis of PHAT was confirmed by examination of the surgical resection specimens. This case showed significant FDG accumulation relative to its pathological low-grade malignant nature.A 10-year-old boy presented with back pain. Tc-methylene diphosphonate bone scan de